舒眠胶囊联合抗抑郁药物对不伴有精神病性症状的抑郁发作患者睡眠障碍的改善效果探讨  

Exploration of the improvement effect of Shumian capsule combined with antidepressant drugs on improving sleep disorder in patients with depressive episodes not accompanied by psychotic symptoms

作　　者：易东晓 YI Dong-xiao(Department of Psychology and Psychiatry,Fuding Hospital Affiliated to Fujian University of Traditional Chinese Medicine,Ningde 355200,China)

机构地区：[1]福建中医药大学附属福鼎市医院心理精神科,355200

出　　处：《中国现代药物应用》2025年第6期114-117,共4页Chinese Journal of Modern Drug Application

摘　　要：目的评价舒眠胶囊联合抗抑郁药物对不伴有精神病性症状的抑郁发作患者睡眠障碍的改善效果。方法86例不伴有精神病性症状的抑郁发作伴睡眠障碍患者,依据随机数表法分为对照组(抗抑郁药物治疗)和观察组(抗抑郁药物、舒眠胶囊联合治疗),每组43例。比较两组患者的睡眠质量评分、汉密尔顿焦虑量表(HAMA)评分、汉密尔顿抑郁量表(HAMD)评分、不良反应发生率、生活质量评分。结果治疗后,观察组患者的睡眠质量、入睡时间、睡眠时间、睡眠障碍、睡眠效率、催眠药物以及日间功能障碍评分分别为(1.33±0.21)、(0.88±0.27)、(0.74±0.16)、(1.28±0.23)、(1.09±0.17)、(0.76±0.18)、(1.28±0.22)分,比对照组的(1.72±0.37)、(1.22±0.36)、(1.11±0.29)、(1.54±0.33)、(1.33±0.26)、(1.18±0.22)、(1.57±0.34)分低,差异有统计意义(P<0.05)。治疗后,两组患者的HAMA、HAMD评分均下降,且观察组患者的HAMA评分(7.24±1.12)分、HAMD评分(7.35±1.26)分均明显比对照组的(11.55±2.05)、(12.27±2.11)分更低,差异有统计意义(P<0.05)。观察组患者用药后的不良反应发生率4.65%比对照组的20.93%更低,差异有统计意义(P<0.05)。治疗后,观察组患者的活动、日常生活、健康、支持和总体状态评分比对照组显著更高,差异有统计意义(P<0.05)。结论针对临床不伴有精神病性症状的抑郁发作伴睡眠障碍患者选择舒眠胶囊联合抗抑郁药物治疗的临床效果更突出,用药安全性高,能有效改善患者的睡眠和心态,促使患者早日康健,值得临床采纳。Objective To evaluate the improvement effect of Shumian capsule combined with antidepressant drugs on improving sleep disorder in patients with depressive episodes not accompanied by psychotic symptoms.Methods 86 patients with depressive episodes not accompanied by psychotic symptoms were divided into the control group(antidepressant drugs)and the observation group(antidepressant drugs and Shumian capsule)according to random numerical table table,with 43 cases in each group.The sleep quality score,Hamilton Anxiety Scale(HAMA)score,Hamilton Depression Scale(HAMD)score,incidence of adverse reactions and quality of life score were compared between the two groups.Results After treatment,the scores of sleep quality, sleep latency, sleep time, sleep disorder, sleep efficiency, hypnotic drugs and daytime dysfunction in the observation group were (1.33±0.21), (0.88±0.27), (0.74±0.16), (1.28±0.23), (1.09±0.17), (0.76±0.18) and (1.28±0.22) points, which were lower than (1.72±0.37), (1.22±0.36), (1.11±0.29), (1.54±0.33), (1.33±0.26), (1.18±0.22) and (1.57±0.34) points in the control group, and the difference was statistically significant (P<0.05). After treatment, HAMA and HAMD scores decreased in both groups;the observation group had HAMA score of (7.24±1.12) points and HAMD score of (7.35±1.26) points, which were significantly lower than (11.55±2.05) and (12.27±2.11) points in the control group, and the differences were statistically significant (P<0.05). The incidence of adverse reactions (4.65%) in the observation group was lower than that in the control group (20.93%), and the difference was statistically significant (P<0.05). Compared with the control group, the scores of activity, daily life, health, support and overall status in the observation group were significantly higher after treatment, and the difference was statistically significant (P<0.05). Conclusion For patients with depressive episodes and sleep disorders not accompanied by psychotic symptoms, the combination therapy of Shumian capsule

关 键 词：舒眠胶囊 抗抑郁药物 不伴有精神病性症状 抑郁发作 睡眠障碍 症状改善 

分 类 号：R749.4[医药卫生—神经病学与精神病学]